Six of the patients, of whom four had non-renal SLE, had follow-up of at least 24 weeks. Of those, five showed dramatic ...

A retrospective study presented at the recent American Society of Clinical Oncology (ASCO) meeting suggested that patients ...

T cells are the immune system’s frontline fighters. When they detect danger, they rapidly multiply and transform into ...

In modern immunotherapy, modified immune cells are introduced into the body to attack tumors and other targets. Researchers ...

Genrix’s velinotamig complements Cullinan’s own pipeline, according to William Blair, which added that the deal will put ...

The deal gives Cullinan T cell engagers aimed at BCMA and CD19, which drugmakers are exploring as possible targets for ...

Scientists with the Fralin Biomedical Research Institute at VTC have created an engineered model of the supportive tissue ...

KITE-363, a dual-targeting CAR T-cell therapy, shows a strong safety profile and high responses in patients who have highly ...

Adding IL-12 to mRNA vaccines can lead to longer lasting protective effect and a potential approach for reducing the risk of ...

Cullinan Therapeutics has announced a licensing agreement with Genrix Bio for global rights to velinotamig, a clinical-stage ...

Cabaletta announced promising results of its lead T-cell therapy candidate targeting autoimmune diseases. Eagles owner ...